deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04643405

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

An Open Label, Multiple Centers Phase Ib/II Study of APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Sponsor: Ascentage Pharma Group Inc.

Conditions Advanced Pancreatic Cancer
Interventions APG-1387 for Injection Gemcitabine Nab paclitaxel
Updated 11 times since 2020 Last updated: Jan 7, 2026 Started: Mar 17, 2021 Primary completion: Jun 25, 2024 Completion: Dec 10, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company Strategy

Other terminated trials from Ascentage Pharma Group Inc.

More terminations from Ascentage Pharma Group Inc.

Other Advanced Pancreatic Cancer trials with similar outcome

Browse all Advanced Pancreatic Cancer trials

Listed as NCT04643405, this PHASE1/PHASE2 trial focuses on Advanced Pancreatic Cancer and remains terminated or withdrawn. Sponsored by Ascentage Pharma Group Inc., it has been updated 11 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotNot Yet Recruiting~Jan 2021 – ~May 2021 · 4 months · monthly snapshotNot Yet Recruiting~May 2021 – ~Sep 2021 · 4 months · monthly snapshotRecruiting~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshotRecruiting~Feb 2022 – ~Apr 2023 · 14 months · monthly snapshotRecruiting~Apr 2023 – ~Oct 2023 · 6 months · monthly snapshotRecruiting~Oct 2023 – ~Apr 2024 · 6 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Feb 2026 · 17 months · monthly snapshotRecruiting~Feb 2026 – present · 7 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE1/PHASE2

    Status: Recruiting → Terminated

  2. Sep 2024 — Feb 2026 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Oct 2023 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Apr 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. Feb 2022 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Jan 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ascentage Pharma Group Inc.
Data source: Ascentage Pharma Group Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations